Drug Trial Radar · NCT00330668
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
Last checked: Nov 20, 2026Latest source record: Aug 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
114
Actual
Start
Nov 2005
Primary completion
Feb 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and adolescents treated for primary IGF-1 deficiency (IGFD). The secondary objective is to use the data collected to learn more about the relationship of IGF-1 exposure to the promotion of normal growth and pubertal development.
Conditions
- Growth Disorders
Interventions
rh IGF-1 (mecasermin)Drug
Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Height Velocity During BID Dosing PeriodTime frame: At Years 1, 2 and 3 in BID dosing period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ipsen
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.